Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Capital Employed: 2017-2025

Historic Return on Capital Employed for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to -0.09%.

  • Anaptysbio's Return on Capital Employed rose 26.00% to -0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.09%, marking a year-over-year increase of 26.00%. This contributed to the annual value of -0.27% for FY2024, which is 6.00% up from last year.
  • Anaptysbio's Return on Capital Employed amounted to -0.09% in Q3 2025, which was up 62.68% from -0.25% recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Return on Capital Employed ranged from a high of 0.02% in Q3 2021 and a low of -0.43% during Q2 2024.
  • Its 3-year average for Return on Capital Employed is -0.30%, with a median of -0.28% in 2023.
  • As far as peak fluctuations go, Anaptysbio's Return on Capital Employed dropped by 22bps in 2022, and later climbed by 26bps in 2025.
  • Quarterly analysis of 5 years shows Anaptysbio's Return on Capital Employed stood at -0.11% in 2021, then declined by 9bps to -0.20% in 2022, then declined by 18bps to -0.38% in 2023, then increased by 12bps to -0.26% in 2024, then rose by 26bps to -0.09% in 2025.
  • Its Return on Capital Employed stands at -0.09% for Q3 2025, versus -0.25% for Q2 2025 and -0.25% for Q1 2025.